abstract |
The disclosure relates to a monoclonal antibody, designated MAbH11B2C2, that binds specifically with a human hyaluronan-binding protein, designated H11B2C2. This protein can occur in two forms, one (apparently expressed by all malignant cells) having an apparent molecular size (as assessed by SDS-PAGE) of about 57 KDa, and another having an apparent molecular size of about 37 KDa. H11B2C2 is expressed by all malignant cell types tested, but does not appear to be significantly expressed by non-tumor cells. H11B2C2 can be used as a marker of malignant status, and MAbH11B2C2 can be used as a reagent for detecting malignant cells, for delivering agents to malignant cells, or both. |